Profile data is unavailable for this security.
About the company
Sareum Holdings plc is a United Kingdom-based biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's internal programs focus on distinct dual tyrosine kinase 2 (TYK2)/ Janus kinase 1 (JAK1) inhibitors, which are progressing through preclinical development as therapies for autoimmune diseases and cancers. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. It is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. The Company also has an interest in SRA737, an orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and a central mediator of the DNA damage response (DDR) network.
- Revenue in GBP (TTM)0.00
- Net income in GBP-4.26m
- Incorporated2004
- Employees5.00
- LocationSareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
- Phone+44 122 349 7700
- Fax+44 122 349 7701
- Websitehttps://sareum.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shield Therapeutics PLC | 13.09m | -33.29m | 18.77m | 73.00 | -- | 1.25 | -- | 1.43 | -0.0458 | -0.0458 | 0.0181 | 0.0192 | 0.347 | 3.65 | 1.31 | 179,246.60 | -88.29 | -56.68 | -136.30 | -67.44 | 30.78 | 52.20 | -254.44 | -365.89 | 2.04 | -30.01 | 0.5739 | -- | 137.95 | 1.95 | 33.13 | -- | -2.50 | -- |
Incanthera PLC | 0.00 | -1.48m | 18.86m | 8.00 | -- | -- | -- | -- | -0.0192 | -0.0192 | 0.00 | -0.0086 | 0.00 | -- | -- | 0.00 | -373.20 | -101.74 | -- | -132.88 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -36.11 | -- | -- | -- |
Oncimmune Holdings PLC | 1.15m | -6.15m | 18.98m | 56.00 | -- | 28.89 | -- | 16.48 | -0.0859 | 0.0507 | 0.0159 | 0.0089 | 0.1239 | 1.08 | 0.5941 | -- | -66.15 | -- | -131.46 | -- | 68.75 | -- | -533.94 | -- | 3.75 | -1.96 | 0.8897 | -- | -- | -- | -- | -- | -- | -- |
Verici DX PLC | 14.96k | -8.83m | 19.43m | 14.00 | -- | 2.59 | -- | 1,298.50 | -0.0518 | -0.0518 | 0.00009 | 0.0309 | 0.0013 | -- | 0.1152 | 997.61 | -77.76 | -- | -92.28 | -- | 84.21 | -- | -59,015.79 | -- | -- | -- | 0.0232 | -- | -- | -- | -36.94 | -- | -- | -- |
Skinbiotherapeutics PLC | 161.65k | -2.88m | 20.04m | 11.00 | -- | 5.21 | -- | 123.96 | -0.0165 | -0.0165 | 0.0009 | 0.0192 | 0.0522 | 0.8871 | 0.4181 | 14,695.45 | -93.07 | -52.07 | -115.26 | -57.33 | 62.90 | -- | -1,784.70 | -4,694.37 | 6.48 | -379.78 | 0.0259 | -- | 76.65 | -- | -1.52 | -- | 18.00 | -- |
Hemogenyx Pharmaceuticals PLC | 0.00 | -6.69m | 20.33m | 17.00 | -- | 6.32 | -- | -- | -0.0061 | -0.0061 | 0.00 | 0.0024 | 0.00 | -- | -- | 0.00 | -101.47 | -82.19 | -112.85 | -95.97 | -- | -- | -- | -- | -- | -28.03 | 0.5144 | -- | -- | -- | -68.14 | -- | 36.68 | -- |
Oxford Biodynamics PLC | 510.00k | -10.83m | 24.64m | 45.00 | -- | 2.64 | -- | 48.31 | -0.0729 | -0.0729 | 0.0035 | 0.0299 | 0.0371 | 0.7987 | 0.332 | 11,333.33 | -78.82 | -39.72 | -105.32 | -45.52 | 52.16 | -- | -2,122.75 | -1,324.62 | 1.72 | -7.50 | 0.5154 | -- | 231.17 | -15.53 | -61.34 | -- | -1.60 | -- |
CRUSHMETRIC Group Ltd | 393.08k | -867.85k | 30.08m | 20.00 | -- | 1.19 | -- | 76.53 | -0.0071 | -0.0071 | 0.0027 | 0.1048 | 0.0255 | 7.14 | 2.64 | 19,653.95 | -5.72 | -40.65 | -8.35 | -- | 34.66 | 37.39 | -224.56 | -140.54 | 0.072 | -14.42 | 0.0558 | -- | 119.19 | -1.40 | -7.26 | -- | 12.11 | -- |
Science in Sport PLC | 65.93m | -7.07m | 35.09m | 158.00 | -- | 0.8816 | -- | 0.5322 | -0.0464 | -0.0464 | 0.4239 | 0.2184 | 0.8479 | 4.20 | 3.83 | 417,278.50 | -9.09 | -9.69 | -13.75 | -11.97 | 41.88 | 47.09 | -10.72 | -11.94 | 0.6921 | -2.31 | 0.2825 | -- | 1.97 | 32.50 | -96.47 | -- | 49.81 | -- |
Sareum Holdings Plc | 0.00 | -4.26m | 36.16m | 5.00 | -- | 56.45 | -- | -- | -0.0614 | -0.0614 | 0.00 | 0.0059 | 0.00 | -- | -- | 0.00 | -160.20 | -71.41 | -195.05 | -81.48 | -- | -- | -- | -19,709.24 | -- | -6.61 | 0.00 | -- | -- | -- | -46.96 | -- | -- | -- |
Arecor Therapeutics PLC | 4.57m | -8.55m | 48.54m | 51.00 | -- | 5.10 | -- | 10.62 | -0.28 | -0.28 | 0.1495 | 0.3111 | 0.2462 | -- | 1.27 | -- | -46.06 | -- | -60.53 | -- | -- | -- | -187.05 | -- | 2.02 | -- | 0.0343 | -- | 90.30 | -- | 7.62 | -- | -- | -- |
Venture Life Group PLC | 51.41m | 921.00k | 49.33m | 165.00 | 73.17 | 0.647 | 6.10 | 0.9596 | 0.0053 | 0.0053 | 0.3847 | 0.6028 | 0.42 | 2.80 | 3.15 | 311,575.80 | 0.7525 | 1.58 | 0.9274 | 1.83 | 39.19 | 40.14 | 1.79 | 3.99 | 0.7355 | 2.12 | 0.2424 | 0.00 | 16.89 | 22.33 | 77.12 | 31.30 | 18.85 | -- |
Holder | Shares | % Held |
---|---|---|
Hargreaves Lansdown Asset Management Ltd.as of 01 Apr 2024 | 4.57m | 4.27% |
HSBC Global Asset Management (UK) Ltd.as of 01 Apr 2024 | 3.29m | 3.08% |
Jarvis Investment Management Ltd.as of 01 Apr 2024 | 1.20m | 1.12% |
IG Markets Ltd.as of 01 Apr 2024 | 420.00k | 0.39% |
Rowan Dartington & Co. Ltd. (Broker)as of 01 Apr 2024 | 172.00k | 0.16% |
Evelyn Partners Investment Management Services Ltd.as of 01 Apr 2024 | 117.00k | 0.11% |
KW Investment Management Ltd.as of 01 Apr 2024 | 108.00k | 0.10% |
iDealing.com Ltd.as of 01 Apr 2024 | 92.00k | 0.09% |
Eurizon Capital SGR SpAas of 01 Apr 2024 | 91.00k | 0.09% |
J. M. Finn & Co. Ltd.as of 01 Apr 2024 | 89.00k | 0.08% |